Lipocine Inc.
General ticker "LPCN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $18.4M (TTM average)
Lipocine Inc. follows the US Stock Market performance with the rate: 29.5%.
Estimated limits based on current volatility of 5.0%: low 8.11$, high 8.97$
Factors to consider:
- Earnings expected soon, date: 2026-03-12 bmo
- Total employees count: 16 (-5.9%) as of 2024
- Top business risk factors: Regulatory and compliance, Clinical trial delays, Operational and conduct risks, Market competition, Labor/talent shortage/retention
- Current price 31.1% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.74$, 6.51$]
- 2025-12-31 to 2026-12-31 estimated range: [2.65$, 6.25$]
Short-term LPCN quotes
Long-term LPCN plot with estimates
Financial data
| YTD | 2024-12-31 |
|---|---|
| Operating Revenue | $11.20MM |
| Operating Expenses | $12.35MM |
| Operating Income | $-1.16MM |
| Non-Operating Income | $1.16MM |
| R&D Expense | $7.35MM |
| Income(Loss) | $0.01MM |
| Taxes | $0.00MM |
| Profit(Loss)* | $0.01MM |
| Stockholders Equity | $21.00MM |
| Assets | $22.51MM |
| Operating Cash Flow | $-1.22MM |
| Capital expenditure | $0.09MM |
| Investing Cash Flow | $2.45MM |
| Financing Cash Flow | $0.21MM |
| Earnings Per Share** | $0.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.